GlassScriptPhysician profile
Young J Lee
NPI 1073153805
$4,656.29
in general payments reported to CMS, 2019-2025
28 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,083 · 2023: $1,429 · 2024: $869 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.49 |
| Education | $291.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $494.04 | 2022-2025 | |
| Abbvie INC. | $482.43 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $441.48 | 2022-2025 | Dupixent |
| Incyte Corporation | $432.82 | 2022-2025 | Opzelura |
| Pfizer INC. | $347.72 | 2022-2025 | |
| Leo Pharma INC. | $287.01 | 2022-2025 | Adbry |
| Ucb, INC. | $278.77 | 2022-2025 | Bimzelx, Cimzia |
| Almirall LLC | $229.75 | 2025 | Seysara |
| Novartis Pharmaceuticals Corporation | $198.60 | 2023-2025 | |
| Lilly USA, LLC | $188.76 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Janssen Biotech, INC. | $175.81 | 2023-2025 | Tremfya |
| Revance Therapeutics, INC. | $157.74 | 2024-2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $132.17 | 2022-2023 | Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $130.61 | 2022-2025 | Jublia, Cabtreo, Arazlo |
| Allergan, INC. | $120.30 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $100.01 | 2023 | |
| Amgen INC. | $75.79 | 2022-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $70.60 | 2024-2025 | Zoryve |
| Strata Skin Sciences, INC. | $66.62 | 2023 | Xtrac |
| Galderma Laboratories, L.P. | $53.49 | 2023 | Aklief, Twyneo, Oracea |
| Botanix Sb INC | $41.24 | 2025 | Sofdra |
| Journey Medical Corporation | $32.54 | 2022-2025 | |
| Dermavant Sciences, INC. | $28.21 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.48 | 2022 | |
| Angiodynamics, INC. | $20.40 | 2022 | |
| Verrica Pharmaceuticals INC. | $14.75 | 2024 | Ycanth |
| Organon LLC | $9.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.